Literature DB >> 26831672

Continuous infusion of β-lactam antibiotics for all critically ill patients?

Fabio S Taccone1, Kevin B Laupland2, Philippe Montravers3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26831672     DOI： 10.1007/s00134-016-4241-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  13 in total

1.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Authors:  Thomas P Lodise; Ben Lomaestro; George L Drusano
Journal:  Clin Infect Dis       Date:  2007-01-02       Impact factor: 9.079

2.  Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Authors:  Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora
Journal:  Int J Antimicrob Agents       Date:  2009-01-15       Impact factor: 5.283

3.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

4.  Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.

Authors:  Joël Cousson; Thierry Floch; Thomas Guillard; Véronique Vernet; Pascal Raclot; Aurore Wolak-Thierry; Damien Jolly
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

5.  Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Authors:  Mohd H Abdul-Aziz; Jeffrey Lipman; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Joel Dulhunty; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2015-10-03       Impact factor: 5.790

6.  Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis.

Authors:  David Zhang; Scott T Micek; Marin H Kollef
Journal:  Crit Care Med       Date:  2015-10       Impact factor: 7.598

7.  Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.

Authors:  R Nalda-Molina; A Dokoumetzidis; G Charkoftaki; E Dimaraki; K Margetis; H Archontaki; S Markantonis; N Boutos; D Sakas; E Vryonis; A Skoutelis; G Valsami
Journal:  J Antimicrob Chemother       Date:  2012-03-28       Impact factor: 5.790

8.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

Authors:  Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

9.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

10.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440
View more
  3 in total

1.  Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.

Authors:  Cédric Carrié; Grégoire Chadefaux; Noémie Sauvage; Hugues de Courson; Laurent Petit; Karine Nouette-Gaulain; Bruno Pereira; Matthieu Biais
Journal:  Crit Care       Date:  2019-11-27       Impact factor: 9.097

2.  Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the 'Maximum Tolerable Dose'.

Authors:  Sofie A M Dhaese; Eric A Hoste; Jan J De Waele
Journal:  Antibiotics (Basel)       Date:  2022-07-04

3.  Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?

Authors:  Helena Colom-Codina; Ariadna Padullés-Zamora; Erika Esteve-Pitarch; Víctor Daniel Gumucio-Sanguino; Sara Cobo-Sacristán; Evelyn Shaw; Kristel Maisterra-Santos; Joan Sabater-Riera; Xosé L Pérez-Fernandez; Raül Rigo-Bonnin; Fe Tubau-Quintano; Jordi Carratalà
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-06-15       Impact factor: 2.441
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.